What Will Happen to Medicure Inc Next? The Stock Just Reaches All-Time High

 What Will Happen to Medicure Inc Next? The Stock Just Reaches All Time High

The stock of Medicure Inc (CVE:MPH) reached all time high today, Nov, 29 and still has $9.04 target or 9.00% above today’s $8.29 share price. This indicates more upside for the $132.07 million company. This technical setup was reported by Barchart.com. If the $9.04 PT is reached, the company will be worth $11.89 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 5,313 shares traded hands. Medicure Inc (CVE:MPH) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.

More news for Medicure Inc (CVE:MPH) were recently published by: Midasletter.com, which released: “S&P/TSX Venture Composite Index Movers: GoldMoney Inc., Medicure Inc …” on February 02, 2016. Seekingalpha.com‘s article titled: “Undervalued And Underfollowed; Medicure Is My Favorite Pharma Small Cap” and published on February 17, 2016 is yet another important article.

Medicure Inc. is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The company has a market cap of $132.07 million. The Firm operates in the biopharmaceutical industry segment. It has a 29.22 P/E ratio. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc.

MPH.V Company Profile

Medicure Inc. (Medicure), incorporated on February 23, 2000, is a pharmaceutical firm engaged in the research, clinical development and commercialization of human therapeutics. The Firm operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc. The Firm is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment